Literature DB >> 28923368

Insights into the structural biology of Gaucher disease.

Laura Smith1, Stephen Mullin1, Anthony H V Schapira2.   

Abstract

Gaucher disease, the most common lysosomal storage disorder, is caused by mutations in the gene encoding the acid-β-glucosidase lysosomal hydrolase enzyme that cleaves glucocerebroside into glucose and ceramide. Reduced enzyme activity and impaired structural stability arise due to >300 known disease-causing mutations. Several of these mutations have also been associated with an increased risk of Parkinson disease (PD). Since the discovery of the acid-β-glucosidase X-ray structure, there have been major advances in our understanding of the structural properties of the protein. Analysis of specific residues has provided insight into their functional and structural importance and provided insight into the pathogenesis of Gaucher disease and the contribution to PD. Disease-causing mutations are positioned throughout the acid-β-glucosidase structure, with many located far from the active site and thus retaining some enzymatic activity however, thus far no clear relationship between mutation location and disease severity has been established. Here, we review the crystal structure of acid-β-glucosidase, while highlighting important structural aspects of the protein in detail. This review discusses the structural stability of acid-β-glucosidase, which can be altered by pH and glycosylation, and explores the relationship between known Gaucher disease and PD mutations, structural stability and disease severity.
Copyright © 2017. Published by Elsevier Inc.

Entities:  

Keywords:  Alpha-synuclein; Glucocerebrosidase; Lysosome; Parkinson disease; Protein structure

Mesh:

Substances:

Year:  2017        PMID: 28923368     DOI: 10.1016/j.expneurol.2017.09.010

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  20 in total

1.  Neurochemical abnormalities in patients with type 1 Gaucher disease on standard of care therapy.

Authors:  Reena V Kartha; James Joers; Marcia R Terluk; Abigail Travis; Kyle Rudser; Paul J Tuite; Neal J Weinreb; Jeanine R Jarnes; James C Cloyd; Gülin Öz
Journal:  J Inherit Metab Dis       Date:  2019-12-17       Impact factor: 4.982

2.  Computational modelling approaches as a potential platform to understand the molecular genetics association between Parkinson's and Gaucher diseases.

Authors:  D Thirumal Kumar; Hend Ghasan Eldous; Zainab Alaa Mahgoub; C George Priya Doss; Hatem Zayed
Journal:  Metab Brain Dis       Date:  2018-07-06       Impact factor: 3.584

Review 3.  GBA1 and The Immune System: A Potential Role in Parkinson's Disease?

Authors:  Zaid A M Al-Azzawi; Saman Arfaie; Ziv Gan-Or
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

4.  LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson's disease.

Authors:  Maria Kedariti; Emanuele Frattini; Pascale Baden; Susanna Cogo; Laura Civiero; Elena Ziviani; Gianluca Zilio; Federico Bertoli; Massimo Aureli; Alice Kaganovich; Mark R Cookson; Leonidas Stefanis; Matthew Surface; Michela Deleidi; Alessio Di Fonzo; Roy N Alcalay; Hardy Rideout; Elisa Greggio; Nicoletta Plotegher
Journal:  NPJ Parkinsons Dis       Date:  2022-07-19

5.  Deep phenotyping for precision medicine in Parkinson's disease.

Authors:  Ann-Kathrin Schalkamp; Nabila Rahman; Jimena Monzón-Sandoval; Cynthia Sandor
Journal:  Dis Model Mech       Date:  2022-06-01       Impact factor: 5.732

6.  Combination of acid β-glucosidase mutation and Saposin C deficiency in mice reveals Gba1 mutation dependent and tissue-specific disease phenotype.

Authors:  Benjamin Liou; Wujuan Zhang; Venette Fannin; Brian Quinn; Huimin Ran; Kui Xu; Kenneth D R Setchell; David Witte; Gregory A Grabowski; Ying Sun
Journal:  Sci Rep       Date:  2019-04-03       Impact factor: 4.379

Review 7.  Neurological effects of glucocerebrosidase gene mutations.

Authors:  S Mullin; D Hughes; A Mehta; A H V Schapira
Journal:  Eur J Neurol       Date:  2018-12-13       Impact factor: 6.089

Review 8.  GBA, Gaucher Disease, and Parkinson's Disease: From Genetic to Clinic to New Therapeutic Approaches.

Authors:  Giulietta M Riboldi; Alessio B Di Fonzo
Journal:  Cells       Date:  2019-04-19       Impact factor: 6.600

9.  Comprehensive clinical, biochemical and genetic screening reveals four distinct GBA genotypes as underlying variable manifestation of Gaucher disease in a single family.

Authors:  P Cullufi; M Tabaku; C Beetz; S Tomori; V Velmishi; A Gjikopulli; P Bauer; S Wirth; A Rolfs
Journal:  Mol Genet Metab Rep       Date:  2019-10-26

Review 10.  Abnormal Sphingolipid World in Inflammation Specific for Lysosomal Storage Diseases and Skin Disorders.

Authors:  Marta Moskot; Katarzyna Bocheńska; Joanna Jakóbkiewicz-Banecka; Bogdan Banecki; Magdalena Gabig-Cimińska
Journal:  Int J Mol Sci       Date:  2018-01-15       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.